Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

532 ARTÍCULOS , VIENDO DEL 46 AL 60

Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease

Zuccarello E, Acquarone E, Calcagno E, Argyrousi EK, Deng SX, Landry DW, Arancio O, Fiorito J.

Biochem Pharmacol. 2020 Jun;176:113818. doi: 10.1016/j.bcp.2020.113818. Epub 2020 Jan 21.

Crosstalk between the M(1) muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?

Thompson KJ, Tobin AB.

Cell Signal. 2020 Jun;70:109545. doi: 10.1016/j.cellsig.2020.109545. Epub 2020 Jan 21.

"Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease

Rao CV, Asch AS, Carr DJJ, Yamada HY.

Aging Cell. 2020 Mar;19(3):e13109. doi: 10.1111/acel.13109. Epub 2020 Jan 25.

Interpretation of risk loci from genome-wide association studies of Alzheimer's disease

Andrews SJ, Fulton-Howard B, Goate A.

Lancet Neurol. 2020 Apr;19(4):326-335. doi: 10.1016/S1474-4422(19)30435-1. Epub 2020 Jan 24.

Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches

Singh RK.

Curr Neuropharmacol. 2020;18(9):868-882. doi: 10.2174/1570159X18666200128121920.

The Role of Chemokines in Alzheimer's Disease

Jorda A, Campos-Campos J, Iradi A, Aldasoro M, Aldasoro C, Vila JM, Valles SL.

Endocr Metab Immune Disord Drug Targets. 2020;20(9):1383-1390. doi: 10.2174/1871530320666200131110744.

Glycogen synthase kinase-3 signaling in Alzheimer's disease

Lauretti E, Dincer O, Praticò D.

Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118664. doi: 10.1016/j.bbamcr.2020.118664. Epub 2020 Jan 30.

Beyond amyloid: New approaches to Alzheimer's disease treatment

EBioMedicine. 2020 Jan;51:102648. doi: 10.1016/j.ebiom.2020.102648.

The Patient in Your Alzheimer's Disease Study May be in Another: Duplication and Deception in Clinical Trials of Alzheimer's Disease

Shiovitz T, Steinmiller B, Steinmetz C, Perez S, Oseas R.

J Prev Alzheimers Dis. 2020;7(1):43-46. doi: 10.14283/jpad.2020.3.

Sodium Oligomannate: First Approval

Syed YY.

Drugs. 2020 Mar;80(4):441-444. doi: 10.1007/s40265-020-01268-1.

Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease

Ono K, Tsuji M.

Int J Mol Sci. 2020 Jan 31;21(3):952. doi: 10.3390/ijms21030952.

Interaction of opioid with insulin/IGFs signaling in Alzheimer's disease

Salarinasab S, Salimi L, Alidadiani N, Shokrollahi E, Arzhanga P, Karbasforush S, Marofi F, Nasirzadeh M, Rahbarghazi R, Nourazarian A, Nikanfar M.

J Mol Neurosci. 2020 Jun;70(6):819-834. doi: 10.1007/s12031-020-01478-y. Epub 2020 Feb 5.

Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta-Analysis

Davis KAS, Bishara D, Perera G, Molokhia M, Rajendran L, Stewart RJ.

J Am Geriatr Soc. 2020 Mar;68(3):650-658. doi: 10.1111/jgs.16342. Epub 2020 Feb 10.

Low-Dose Radiation Therapy: A New Treatment Strategy for Alzheimer's Disease?

Ceyzériat K, Tournier BB, Millet P, Frisoni GB, Garibotto V, Zilli T.

J Alzheimers Dis. 2020;74(2):411-419. doi: 10.3233/JAD-190984.

Passive antiamyloid immunotherapy for Alzheimer's disease

Loureiro JC, Pais MV, Stella F, Radanovic M, Teixeira AL, Forlenza OV, de Souza LC.

Curr Opin Psychiatry. 2020 May;33(3):284-291. doi: 10.1097/YCO.0000000000000587.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias